Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder
Completed · Phase 1
Conditions studied: Idiopathic Overactive Bladder With Urinary Incontinence
In brief
The purpose of this study is to determine if TAR-302-5018, an investigational drug-delivery system, is safe and tolerable in patients with idiopathic overactive bladder and urinary incontinence.
Key facts
- Study ID
- NCT03109379
- Run by
- Taris Biomedical LLC
- People needed
- 43
- Starts
- 2017-04-04
- Expected to finish
- 2019-09-27
- Last updated by the study team
- 2020-01-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Urological Associates of Southern Arizona — Tucson, Arizona, United States
- Medical Center for Clinical Research — San Diego, California, United States
- Clinical Research Center of Florida — Pompano Beach, Florida, United States
- DelRicht Clinical Research, LLC — New Orleans, Louisiana, United States
- Bay State Clinical Trials, Inc — Watertown, Massachusetts, United States
- William Beaumont Hospital - Royal Oak — Royal Oak, Michigan, United States
- Michigan Institute of Urology — Troy, Michigan, United States
- New Jersey Urology — Voorhees Township, New Jersey, United States
- Accumed Research — Garden City, New York, United States
- Manhattan Medical Resear — New York, New York, United States
- UWCR - Lyndhurst Gynecologic Associates — Winston-Salem, North Carolina, United States
- Urology of Virginia — Virginia Beach, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.